TY  - JOUR
PY  - 2013//
TI  - Sports doping: Emerging designer and therapeutic beta2-agonists
JO  - Clinica chimica acta: international journal of clinical chemistry
A1  - Fragkaki, A. G.
A1  - Georgakopoulos, C.
A1  - Sterk, S.
A1  - Nielen, M. W. F.
SP  - 242
EP  - 258
VL  - 425
IS  - 
N2  - beta2-Adrenergic agonists, or β2-agonists, are considered essential bronchodilator drugs in the treatment of bronchial asthma, both as symptoms-relievers and, in combination with inhaled corticosteroids, as disease-controllers. The use of β2-agonists is prohibited in sports by the World Anti-Doping Agency (WADA) due to claimed anabolic effects, and also, is prohibited as growth promoters in cattle fattening in the European Union. This paper reviews the last seven-year (2006-2012) literature concerning the development of novel β2-agonists molecules either by modifying the molecule of known β2-agonists or by introducing moieties producing indole-, adamantyl- or phenyl urea derivatives. New emerging β2-agonists molecules for future therapeutic use are also presented, intending to emphasize their potential use for doping purposes or as growth promoters in the near future.<p />  <p>Language: en</p>
LA  - en
SN  - 0009-8981
UR  - http://dx.doi.org/10.1016/j.cca.2013.07.031
ID  - ref1
ER  -